Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
17,238
Total Claims
$1.1M
Drug Cost
377
Beneficiaries
$2,966
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-53%
Opioid rate vs peers
1.1% vs 2.2% avg
+110%
Cost per patient vs peers
$2,966 vs $1,411 avg
+10%
Brand preference vs peers
11.7% vs 10.6% avg
Opioid Prescribing
1.1%
Opioid Rate
182
Opioid Claims
$2,889
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,017 claims · $869K
Generic: 15,181 claims · $248K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 563 | $200K |
| Dulaglutide | 57 | $87K |
| Empagliflozin | 68 | $54K |
| Dapagliflozin Propanediol | 54 | $50K |
| Sitagliptin Phosphate | 131 | $41K |
| Semaglutide | 37 | $41K |
| Mirabegron | 147 | $38K |
| Rivaroxaban | 110 | $36K |
| Insulin Glargine,hum.Rec.Anlog | 107 | $36K |
| Fluticasone/Umeclidin/Vilanter | 34 | $33K |
| Liraglutide | 15 | $29K |
| Insulin Lispro | 24 | $15K |
| Sacubitril/Valsartan | 27 | $14K |
| Evolocumab | 11 | $14K |
| Sitagliptin Phos/Metformin Hcl | 17 | $13K |
Prescribing Profile
Patient Profile
75
Avg Age
51%
Female
1.86
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data